ClinicalTrials.gg
CompletedNCT03251378Updated Sep 25, 2024Results posted

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers

A Phase 1 interventional study of Fruquintinib (HMPL-013) in Advanced Solid Tumors, Metastatic Colon Cancer and Metastatic Breast Cancer, sponsored by Hutchison Medipharma Limited. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-25.

Sponsored by Hutchison Medipharma Limited (part of HUTCHMED) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
129
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,122 studies in Colonic Neoplasms with a site in United States — 116 open to participants now, 190 under way, 14 of them phase 3. Colonic Neoplasms · United States.

Enrollment
256th of 864
129 · median 50
Started
2017
with 42 others
Phase 1
244 of 1,122
20 open now
Registered
772nd of 1,122
by date

Among the 1,122 studies in Colonic Neoplasms with a site in United States, this one is the 256th largest by enrollment of the 864 interventional ones that give a count, is one of 43 that started in 2017, is one of 244 in phase 1, and was the 772nd registered.

Colonic Neoplasms

2,456 studies on the registry are indexed under Colonic Neoplasms; 458 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

116 of the 1,122 studies in Colonic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

111 more — sign in →

All 116 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 328 Colonic Neoplasms studies recruiting now, 204 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,122 studies in Colonic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability, and PK of fruquintinib in patients with advanced solid tumors, metastatic colorectal cancer and metastatic breast cancer.

Read the detailed description

The study was an open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability, and PK of fruquintinib in patients with advanced solid tumors. The study consisted of two phases:

  • A dose escalation phase - Two dose cohorts were evaluated including 3 mg orally QD 3 weeks on/1 week off and 5 mg orally QD 3 weeks on/1 week off. A 3+3 design was used for this portion of the study.
  • A dose expansion phase - Five cohorts were evaluated in Dose Expansion phase. Cohort A evaluated the MTD/RP2D in patients with advanced solid tumors of any type. Cohort B and Cohort C evaluated the MTD/RP2D in metastatic colorectal cancer patients. Cohort D and Cohort E evaluated the MTD/RP2D in metastatic breast cancer patients.

Study was conducted at 9 sites in the United States.

03

Conditions studied

  • Advanced Solid Tumors
  • Metastatic Colon Cancer
  • Metastatic Breast Cancer
  • Triple Negative Breast Cancer
  • HER2-negative Breast Cancer
  • Hormone Receptor Positive Breast Carcinoma
  • Rectal Cancer

Keywords

  • VEGF
  • colorectal
  • breast
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Fully understand the study and voluntarily sign the ICF;
  • ≥18years of age;
  • (ECOG) performance status of 0 or 1;

Dose Escalation Phase:

  • or cytologically documented, locally advanced or solid of any type (except squamous NSCLC) that has progressed on approved systemic therapy, and for whom no effective therapy or standard of care exists. This cohort is closed to enrollment.

Dose Expansion Phase:

  • Cohort A: Histologically or cytologically documented, locally advanced or metastatic solid malignancy of any type (except squamous NSCLC), that has progressed on approved systemic therapy, and for whom no effective therapy or standard of care exists. This cohort is closed to enrollment.
  • Cohort B: Histologically or cytologically documented mCRC in patients that have progressed on, or had intolerable toxicity with at least 1 FDA-approved systemic therapy (trifluridine/tipiracil or regorafenib). Patients must also have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and an anti-EGFR therapy for patients who had RAS wild-type tumors. This cohort is currently enrolling.
  • Cohort C: Histologically or cytologically documented adenocarcinoma of the colon or rectum. Patients must have progressed on, or had intolerable toxicity to, at least 2 prior regimens of standard chemotherapy, but must not have received prior TAS-102 or regorafenib. Prior therapy could have included chemotherapy if a tumor had recurred within 6 months after the last administration of treatment. Patients must have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy and, if RAS wild-type, an anti-EGFR therapy
  • Cohort D only: Histologically- or cytologically-confirmed Her2-negative, hormone receptor positive (ER+ and/or PR+) breast cancer
  • Cohort E only: Histologically- or cytologically- confirmed triple negative breast cancer

Key Exclusion Criteria:

Patients will be excluded from the study, if any of the following criteria is met:

  • Severe anemia, neutropenia, thrombocytopenia
  • Moderate to severe renal or hepatic impairment
  • Uncontrolled hypertension
  • Risk of, or active hemorrhage: history or presence of active gastric/duodenal ulcer or ulcerative colitis, active hemorrhage of an unresected gastrointestinal tumor, history of perforation of fistulas; or any other condition that could possibly result in gastrointestinal tract hemorrhage or perforation within 6 months prior to screening;
  • History of a thromboembolic event (including deep vein thrombosis [DVT], pulmonary embolism, stroke and/or ) within 6 months prior to screening;
  • Patients with squamous NSCLC;
  • cardiovascular disease, including but not limited to acute myocardial infarction or coronary artery bypass surgery within 6 months prior to enrollment, severe or unstable angina pectoris, Class III/IV congestive heart failure, ventricular arrhythmias requiring treatment, or (LVEF) \<50%;
  • Patients who have ever received a VEGFR inhibitor, except for patients with mCRC enrolled in the dose expansion phase;
  • Systemic anti-neoplastic therapies or any therapy within 4 weeks prior to the first dose of study drug, including chemotherapy, radical radiotherapy, hormonotherapy, biotherapy and immunotherapy;
  • Systemic small molecule targeted therapies (e.g., tyrosine kinase inhibitors) within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of study drug;
  • Palliative radiotherapy for bone metastasis/lesion within 2 weeks prior to the initiation of study drug;
  • Brachytherapy (ie, implantation of radioactive seeds) within 60 days prior to the first dose of study drug;
  • Known (HIV) infection;
  • Known clinically significant history of liver disease, including cirrhosis, current alcohol abuse or active viral hepatitis. For patients with evidence of chronic (HBV), the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of virus (HCV) infection must have been treated and cured. For patients with HCV who are currently on treatment, they are eligible if they have an undetectable HCV viral load;
  • Tumor invasion of a large vascular structure, eg, pulmonary artery, superior or inferior vena cava.;
  • Women who are pregnant or lactating;
  • and/or spinal cord compression untreated with surgery and/or radiotherapy, and without clinical imaging evidence of stable disease for 14 days or longer; patients requiring within 4 weeks prior to start of study treatment will be excluded;
  • No other malignancy, except for non-melanoma skin cancer, during the 5 years prior to screening;
  • Inability to take medication orally, dysphagia or an active gastric ulcer resulting from previous surgery (eg, gastric bypass) or a severe gastrointestinal disease, or any other condition that investigators believe may affect absorption of the investigational product;
  • Other disease, metabolic disorder, physical examination anomaly, abnormal laboratory result, or any other condition that investigators suspect may prohibit use of the investigational product, affect interpretation of study results, or put the patient at undue risk of harm based on the investigator's assessment;
  • Known to fruquintinib or any of its .
  • For Cohort C only: patients who have been previously treated with TAS-102 or regorafenib
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    3 mg Dose Escalation

    3 mg of Fruquintinib (HMPL-013), capsule taken orally, daily, 3 weeks on, 1 week off

    Drug: Fruquintinib (HMPL-013)

  • Experimental
    5 mg Dose Escalation

    5 mg of Fruquintinib (HMPL-013), capsule taken orally, daily, 3 weeks on, 1 week off

    Drug: Fruquintinib (HMPL-013)

  • Experimental
    Fruquintinib Expansion Cohort A

    5 mg fruquintinib (HMPL-013) capsule taken orally, daily, 3 weeks on, 1 week off in patients with advanced solid tumors of any type.

    Drug: Fruquintinib (HMPL-013)

  • Experimental
    Metastatic Colorectal Cancer Expansion Cohort B (prior trifluridine/tipiracil or regorafenib)

    5 mg fruquintinib (HMPL-013) capsule taken orally, daily, 3 weeks on, 1 week off in patients with metastatic colorectal cancer who have progressed on or had intolerable toxicity to TAS-102, regoragenib, or both.

    Drug: Fruquintinib (HMPL-013)

  • Experimental
    Metastatic Colorectal Cancer Expansion Cohort C (no prior trifluridine/tipiracil or regorafenib)

    5 mg fruquintinib (HMPL-013) capsule taken orally, daily, 3 weeks on, 1 week off in patients with metastatic colorectal cancer who have not been treated with TAS-102 or regorafenib.

    Drug: Fruquintinib (HMPL-013)

  • Experimental
    Metastatic Breast Cancer (HR positive, HER2 negative) Expansion Cohort D

    5 mg fruquintinib (HMPL-013) capsule taken orally, daily, 3 weeks on, 1 week off in patients with metastatic Her2-negative, hormone receptor positive breast cancer.

    Drug: Fruquintinib (HMPL-013)

  • Experimental
    Metastatic Breast Cancer (TNBC) Expansion Cohort E

    5 mg fruquintinib (HMPL-013) capsule taken orally, daily, 3 weeks on, 1 week off in patients with metastatic triple negative (Her2-negative, ER-negative, PR-negative) breast cancer.

    Drug: Fruquintinib (HMPL-013)

Interventions

  • Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class.

    Also known as: HMPL-013

06

What researchers measure

Primary outcomes

  1. Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs)

    Dose-limiting toxicity was defined as: Any Grade 4 non-hematologic toxicity; Any Grade 3 non-hematologic toxicity related to study drug except for nausea/vomiting, diarrhea, constipation, hypertension, and electrolyte imbalances downgraded within 3-days with appropriate supportive treatment; Grade 4 neutropenia lasting \>3 days; Grade 3 febrile neutropenia (absolute neutrophil count \[ANC\] \<1.0\*10\^9 per liter \[/L\] with a single temperature of greater than (\>) 38.3 degree centigrade (°C) or a sustained temperature of greater than or equal to (\>=) 38°C for more than 1 hour); Grade 4 thrombocytopenia or Grade 3 thrombocytopenia associated with bleeding; Dose interruption for \>14 days due to toxicity.

    Time frame: Cycle 1 (cycle length equal to [=] 28 days)

  2. Dose Escalation Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

    TEAEs were defined as AEs that started or worsened in severity on or after the first dose of study medication and no later than 37 days after the date of last study treatment. A serious adverse event (SAE) was any AE that had any of the following characteristics: Fatal (that was, the AE actually caused or led to death, except for deaths caused by the progress of disease); Life threatening (that was, AE, in view of the investigator, places participant at immediate risk of death); Required or prolonged inpatient hospitalization (excluding emergency or outpatient treatment); Resulted in persistent or significant disability/incapacity (that was, the AE resulted in substantial disruption of the participant's ability to conduct normal life functions).

    Time frame: From first dose of study drug up to 37 days after last dose of study drug (i.e., up to 29 months)

  3. Dose Expansion Phase: Progression Free Survival (PFS) Rate

    PFS was defined as time from date of first dosing until date of an objective disease progression (PD) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 or death due to any cause, whichever comes first. PFS was determined using all data until last evaluable visit prior to or on date of: (i) radiographic PD per RECIST v1.1; (ii) withdrawal of consent to obtain additional scans on study; or (iii) initiation of subsequent anticancer therapy other than study drugs, whichever was earlier. PFS rate was defined as probability of being disease progression free at selected timepoints such as 16 weeks and was calculated using Brookmeyer-Crowley method based on PFS events observed up to 29 months. PD:at least 20 percent (%) increase in sum of diameters of target lesions, taking as reference smallest sum on study, including baseline; an absolute increase of at least 5 millimeter (mm) in sum of diameters of target lesions; and appearance of one or more new lesions.

    Time frame: From the first dose of study drug to disease progression, or death, whichever occurred first (i.e., up to 29 months)

Secondary outcomes

  1. Dose Escalation and Expansion Phase: Maximum Observed Plasma Concentration (Cmax) of Fruquintinib

    Cmax of fruquintinib was reported.

    Time frame: Dose Escalation and Cohort A of Expansion Phases: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 1, 14, and 21 of Cycle 1; Cohorts B, C, D, E of Expansion Phase: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 1 and 14 of Cycle 1 (Cycle 1 length=28 days)

  2. Dose Escalation and Expansion Phase: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Fruquintinib

    Tmax of fruquintinib over a dosing intervals were reported.

    Time frame: Dose Escalation and Cohort A of Expansion Phases: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 1, 14, and 21 of Cycle 1; Cohorts B, C, D, E of Expansion Phase: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 1 and 14 of Cycle 1 (Cycle 1 length=28 days)

  3. Dose Escalation and Expansion Phase: Minimum Observed Plasma Concentration (Cmin) of Fruquintinib

    Cmin of fruquintinib was reported.

    Time frame: Dose Escalation and Cohort A of Expansion Phases: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 14, and 21 of Cycle 1; Cohorts B, C, D, E of Expansion Phase: Predose, 1, 2, 4, 8, 24 hours post-dose on Day 14 of Cycle 1 (Cycle 1 length=28 days)

  4. Dose Escalation and Expansion Phase: Time to Reach Minimum Observed Plasma Concentration (Tmin) of Fruquintinib

    Tmin of fruquintinib was reported.

    Time frame: Dose Escalation and Cohort A of Expansion Phases: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 14, and 21 of Cycle 1; Cohorts B, C, D, E of Expansion Phase: Predose, 1, 2, 4, 8, 24 hours post-dose on Day 14 of Cycle 1 (Cycle 1 length=28 days)

  5. Dose Escalation and Expansion Phase: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC0-24) of Fruquintinib

    AUC0-24 of fruquintinib was reported.

    Time frame: Dose Escalation and Cohort A of Expansion Phases: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 1, 14, and 21 of Cycle 1; Cohorts B, C, D, E of Expansion Phase: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 1 and 14 of Cycle 1 (Cycle 1 length=28 days)

  6. Dose Escalation and Expansion Phase: Apparent Clearance at Steady State (CL/Fss) of Fruquintinib

    CL/Fss was calculated as Dose/AUC0-t. As planned, CL/Fss was assessed at Cycle 1 Days 14 and 21 after multiple dose administration in Dose Escalation Phase and Cohort A of Dose Expansion Phase; and at Cycle 1 Day 14 for Cohort B, C, D, E of Expansion Phase.

    Time frame: Dose Escalation and Cohort A of Expansion Phases: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 14, and 21 of Cycle 1; Cohorts B, C, D, E of Expansion Phase: Predose, 1, 2, 4, 8, 24 hours post-dose on Day 14 of Cycle 1 (Cycle 1 length=28 days)

  7. Dose Escalation and Expansion Phase: Accumulation Ratio Based on Cmax of Fruquintinib

    Accumulation ratio based on Cmax for Cycle 1 Day 14 was calculated as Day 14 Cmax /Day 1 Cmax and for Cycle 1 Day 21 was calculated as Day 21 Cmax /Day 1 Cmax. Accumulation ratio based on Cmax of fruquintinib was reported.

    Time frame: Dose Escalation and Cohort A of Expansion Phases: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 14 and 21 of Cycle 1; Cohorts B, C, D, E of Expansion Phase: Predose, 1, 2, 4, 8, 24 hours post-dose on Day 14 of Cycle 1 (Cycle 1 length=28 days)

  8. Dose Escalation and Expansion Phase: Accumulation Ratio Based on AUC0-24 Hours of Fruquintinib

    Accumulation ratio for Cycle 1 Day 14 was calculated as AUC0-24 at Day 14 divided by AUC0-24h at Day 1, and for Cycle 1 Day 21 was calculated as AUC0-24 at Day 21 divided by AUC0-24 at Day 1. Accumulation ratio based on AUC0-24 of fruquintinib was reported.

    Time frame: Dose Escalation and Cohort A of Expansion Phases: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 14 and 21 of Cycle 1; Cohorts B, C, D, E of Expansion Phase: Predose, 1, 2, 4, 8, 24 hours post-dose on Day 14 of Cycle 1 (Cycle 1 length=28 days)

  9. Dose Escalation and Expansion Phase: Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with objective complete response (CR) or partial response (PR) response per RECIST version 1.1. As per RECIST 1.1; CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

    Time frame: From the first dose of study drug until first documentation of best overall response (i.e., up to 29 months)

  10. Dose Escalation and Expansion Phase: Disease Control Rate (DCR)

    DCR was defined as the percentage of participants with a best overall response (BOR) of confirmed CR, confirmed PR or stable disease (SD) (for 7 weeks) per RECIST version 1.1. As per RECIST 1.1; CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study \[this might include the baseline sum\]).

    Time frame: From the first dose of study drug until first documentation of best overall response (i.e., up to 29 months)

  11. Dose Escalation and Expansion Phase: Duration of Response (DoR)

    DoR was defined as the time (in months) from the date of the first objective response (CR or PR) until the date of the documented progression or of death, whichever comes first. DoR was only analyzed for participants whose best overall response (BOR) was either CR or PR. As per RECIST 1.1; CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this might include the baseline sum). DoR was calculated using the Kaplan-Meier method.

    Time frame: From the date of the first objective response (CR or PR) until the date of the documented disease progression or of death, whichever comes first (i.e., up to 29 months)

  12. Dose Escalation and Expansion Phase: Progression Free Survival (PFS)

    PFS was defined as the time (in months) from date of first dosing until the date of an objective disease progression as per RECIST version 1.1 or death due to any cause, whichever comes first. PFS was determined using all the assessment data up until the last evaluable visit prior to or on the date of (i) disease progression as defined by RECIST version 1.1 or death; or (ii) withdrawal of consent; or (iii) receiving subsequent anti-cancer therapy, whichever is earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this might include the baseline sum). PFS was calculated using the Kaplan-Meier method.

    Time frame: From date of first dose until the date of an objective disease progression or death due to any cause, whichever comes first (i.e., up to 29 months)

  13. Dose Escalation and Expansion Phase: Overall Survival (OS)

    OS was defined as the time interval (in months) between the first dose date and the date of death (any cause). OS was calculated using the Kaplan-Meier method.

    Time frame: From first dose date to the date of death (due to any cause) (i.e., up to 29 months)

  14. Dose Escalation and Expansion Phase: Percent Change From Baseline (PCFB) in Tumor Size

    Tumor size was estimated using data on sum of diameters of target lesion. Percentage change in tumor size from baseline was determined for participants with measurable disease at baseline and derived by the percentage change in the sum of the diameters of target lesions (TLs) compared to baseline. Baseline was defined as the last evaluable tumor assessment result obtained prior to the first administration of study medication.

    Time frame: Baseline up to 29 months

  15. Dose Expansion Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

    TEAEs were defined as AEs that started or worsened in severity on or after the first dose of study medication and no later than 37 days after the date of last study treatment. A SAE was any AE that had any of the following characteristics: Fatal (that was, the AE actually caused or led to death, except for deaths caused by the progress of disease); Life threatening (that was, AE, in view of the investigator, places participant at immediate risk of death); Required or prolonged inpatient hospitalization (excluding emergency or outpatient treatment); Resulted in persistent or significant disability/incapacity (that was, the AE resulted in substantial disruption of the participant's ability to conduct normal life functions).

    Time frame: From first dose of study drug up to 37 days after last dose of study drug (i.e., up to 29 months)

07

Results

Posted Sep 25, 2024

Participant flow

The study was conducted at 9 study sites in the United States.

Participant flow — Overall Study
MilestoneDose Escalation Phase: Fruquintinib 3 mgDose Escalation Phase: Fruquintinib 5 mgDose Expansion Phase, Cohort A: Fruquintinib 5 mgDose Expansion Phase, Cohort B: Fruquintinib 5 mgDose Expansion Phase, Cohort C: Fruquintinib 5 mgDose Expansion Phase, Cohort D: Fruquintinib 5 mgDose Expansion Phase, Cohort E: Fruquintinib 5 mg
Started77641401414
Completed0000000
Not completed77641401414
Withdrew: Death32330241212
Withdrew: Lost to follow-up0013000
Withdrew: Patient withdrew consent and refused to provide follow-up information0003211
Withdrew: Progressive disease2001000
Withdrew: Physician decision0200000
Withdrew: Other2320111
Withdrew: Other00041300

Outcome measures

PrimaryDose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs)

Dose-limiting toxicity was defined as: Any Grade 4 non-hematologic toxicity; Any Grade 3 non-hematologic toxicity related to study drug except for nausea/vomiting, diarrhea, constipation, hypertension, and electrolyte imbalances downgraded within 3-days with appropriate supportive treatment; Grade 4 neutropenia lasting \>3 days; Grade 3 febrile neutropenia (absolute neutrophil count \[ANC\] \<1.0\*10\^9 per liter \[/L\] with a single temperature of greater than (\>) 38.3 degree centigrade (°C) or a sustained temperature of greater than or equal to (\>=) 38°C for more than 1 hour); Grade 4 thrombocytopenia or Grade 3 thrombocytopenia associated with bleeding; Dose interruption for \>14 days due to toxicity.

Time frame:
Cycle 1 (cycle length equal to [=] 28 days)
Reported as:
Count of participants · Participants
Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs)
ParticipantsDose Escalation Phase: Fruquintinib 3 mgDose Escalation Phase: Fruquintinib 5 mg
Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs)10
PrimaryDose Escalation Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

TEAEs were defined as AEs that started or worsened in severity on or after the first dose of study medication and no later than 37 days after the date of last study treatment. A serious adverse event (SAE) was any AE that had any of the following characteristics: Fatal (that was, the AE actually caused or led to death, except for deaths caused by the progress of disease); Life threatening (that was, AE, in view of the investigator, places participant at immediate risk of death); Required or prolonged inpatient hospitalization (excluding emergency or outpatient treatment); Resulted in persistent or significant disability/incapacity (that was, the AE resulted in substantial disruption of the participant's ability to conduct normal life functions).

Time frame:
From first dose of study drug up to 37 days after last dose of study drug (i.e., up to 29 months)
Reported as:
Count of participants · Participants
Dose Escalation Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsDose Escalation Phase: Fruquintinib 3 mgDose Escalation Phase: Fruquintinib 5 mg
Participants with TEAEs77
Participants with serious TEAEs32
PrimaryDose Expansion Phase: Progression Free Survival (PFS) Rate

PFS was defined as time from date of first dosing until date of an objective disease progression (PD) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 or death due to any cause, whichever comes first. PFS was determined using all data until last evaluable visit prior to or on date of: (i) radiographic PD per RECIST v1.1; (ii) withdrawal of consent to obtain additional scans on study; or (iii) initiation of subsequent anticancer therapy other than study drugs, whichever was earlier. PFS rate was defined as probability of being disease progression free at selected timepoints such as 16 weeks and was calculated using Brookmeyer-Crowley method based on PFS events observed up to 29 months. PD:at least 20 percent (%) increase in sum of diameters of target lesions, taking as reference smallest sum on study, including baseline; an absolute increase of at least 5 millimeter (mm) in sum of diameters of target lesions; and appearance of one or more new lesions.

Time frame:
From the first dose of study drug to disease progression, or death, whichever occurred first (i.e., up to 29 months)
Reported as:
Number · percentage of participants
Dose Expansion Phase: Progression Free Survival (PFS) Rate
percentage of participantsDose Expansion Phase, Cohort A: Fruquintinib 5 mgDose Expansion Phase, Cohort B: Fruquintinib 5 mgDose Expansion Phase, Cohort C: Fruquintinib 5 mgDose Expansion Phase, Cohort D: Fruquintinib 5 mgDose Expansion Phase, Cohort E: Fruquintinib 5 mg
Dose Expansion Phase: Progression Free Survival (PFS) Rate53.33 (4.68 to 100.00)61.04 (45.59 to 76.49)55.64 (39.87 to 71.41)29.30 (1.91 to 56.70)38.46 (12.02 to 64.91)
SecondaryDose Escalation and Expansion Phase: Maximum Observed Plasma Concentration (Cmax) of Fruquintinib

Cmax of fruquintinib was reported.

Time frame:
Dose Escalation and Cohort A of Expansion Phases: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 1, 14, and 21 of Cycle 1; Cohorts B, C, D, E of Expansion Phase: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 1 and 14 of Cycle 1 (Cycle 1 length=28 days)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Dose Escalation and Expansion Phase: Maximum Observed Plasma Concentration (Cmax) of Fruquintinib
nanogram per milliliter (ng/mL)Dose Escalation Phase: Fruquintinib 3 mgDose Escalation Phase: Fruquintinib 5 mgDose Expansion Phase, Cohort A: Fruquintinib 5 mgDose Expansion Phase, Cohort B: Fruquintinib 5 mgDose Expansion Phase, Cohort C: Fruquintinib 5 mgDose Expansion Phase, Cohort D: Fruquintinib 5 mgDose Expansion Phase, Cohort E: Fruquintinib 5 mg
Cycle 1 Day 152.2 ± 24.2114 ± 27.596.0 ± 23.085.2 ± 32.189.0 ± 43.2104 ± 37.0105 ± 36.5
Cycle 1 Day 14198 ± 9.8403 ± 33.7336 ± 50.9271 ± 26.5293 ± 27.1331 ± 36.1352 ± 23.4
Cycle 1 Day 21205 ± 12.8390 ± 19.1238 ± NA————
SecondaryDose Escalation and Expansion Phase: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Fruquintinib

Tmax of fruquintinib over a dosing intervals were reported.

Time frame:
Dose Escalation and Cohort A of Expansion Phases: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 1, 14, and 21 of Cycle 1; Cohorts B, C, D, E of Expansion Phase: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 1 and 14 of Cycle 1 (Cycle 1 length=28 days)
Reported as:
Median · hours
Dose Escalation and Expansion Phase: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Fruquintinib
hoursDose Escalation Phase: Fruquintinib 3 mgDose Escalation Phase: Fruquintinib 5 mgDose Expansion Phase, Cohort A: Fruquintinib 5 mgDose Expansion Phase, Cohort B: Fruquintinib 5 mgDose Expansion Phase, Cohort C: Fruquintinib 5 mgDose Expansion Phase, Cohort D: Fruquintinib 5 mgDose Expansion Phase, Cohort E: Fruquintinib 5 mg
Cycle 1 Day 12.07 (1.03 to 21.2)1.95 (0.917 to 25.0)1.96 (1.00 to 13.8)2.25 (0.917 to 23.8)2.04 (0.983 to 2.04)2.00 (1.00 to 18.4)2.01 (1.75 to 23.9)
Cycle 1 Day 141.03 (0.967 to 1.92)2.00 (1.97 to 7.05)1.52 (1.00 to 2.03)2.03 (0.00 to 26.1)2.00 (0.933 to 7.18)1.86 (0.917 to 7.00)1.84 (0.933 to 7.00)
Cycle 1 Day 211.83 (0.917 to 1.98)2.00 (1.88 to 4.08)1.00 (NA to NA)————
SecondaryDose Escalation and Expansion Phase: Minimum Observed Plasma Concentration (Cmin) of Fruquintinib

Cmin of fruquintinib was reported.

Time frame:
Dose Escalation and Cohort A of Expansion Phases: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 14, and 21 of Cycle 1; Cohorts B, C, D, E of Expansion Phase: Predose, 1, 2, 4, 8, 24 hours post-dose on Day 14 of Cycle 1 (Cycle 1 length=28 days)
Reported as:
Mean · ng/mL
Dose Escalation and Expansion Phase: Minimum Observed Plasma Concentration (Cmin) of Fruquintinib
ng/mLDose Escalation Phase: Fruquintinib 3 mgDose Escalation Phase: Fruquintinib 5 mgDose Expansion Phase, Cohort A: Fruquintinib 5 mgDose Expansion Phase, Cohort B: Fruquintinib 5 mgDose Expansion Phase, Cohort C: Fruquintinib 5 mgDose Expansion Phase, Cohort D: Fruquintinib 5 mgDose Expansion Phase, Cohort E: Fruquintinib 5 mg
Cycle 1 Day 14138 ± 28.3281 ± 101251 ± 114193 ± 57.3204 ± 63.2227 ± 98.4249 ± 72.1
Cycle 1 Day 21140 ± 27.0283 ± 81.0182 ± NA————
SecondaryDose Escalation and Expansion Phase: Time to Reach Minimum Observed Plasma Concentration (Tmin) of Fruquintinib

Tmin of fruquintinib was reported.

Time frame:
Dose Escalation and Cohort A of Expansion Phases: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 14, and 21 of Cycle 1; Cohorts B, C, D, E of Expansion Phase: Predose, 1, 2, 4, 8, 24 hours post-dose on Day 14 of Cycle 1 (Cycle 1 length=28 days)
Reported as:
Median · hours
Dose Escalation and Expansion Phase: Time to Reach Minimum Observed Plasma Concentration (Tmin) of Fruquintinib
hoursDose Escalation Phase: Fruquintinib 3 mgDose Escalation Phase: Fruquintinib 5 mgDose Expansion Phase, Cohort A: Fruquintinib 5 mgDose Expansion Phase, Cohort B: Fruquintinib 5 mgDose Expansion Phase, Cohort C: Fruquintinib 5 mgDose Expansion Phase, Cohort D: Fruquintinib 5 mgDose Expansion Phase, Cohort E: Fruquintinib 5 mg
Cycle 1 Day 140.00 (0.00 to 7.00)0.508 (0.00 to 27.8)3.57 (0.00 to 7.13)0.00 (0.00 to 25.6)0.00 (0.00 to 28.2)0.00 (0.00 to 23.9)0.458 (0.00 to 22.0)
Cycle 1 Day 217.00 (0.00 to 25.6)3.54 (0.00 to 24.9)7.00 (NA to NA)————
SecondaryDose Escalation and Expansion Phase: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC0-24) of Fruquintinib

AUC0-24 of fruquintinib was reported.

Time frame:
Dose Escalation and Cohort A of Expansion Phases: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 1, 14, and 21 of Cycle 1; Cohorts B, C, D, E of Expansion Phase: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 1 and 14 of Cycle 1 (Cycle 1 length=28 days)
Reported as:
Geometric mean · hour*nanogram per millimeter (h*ng/mL)
Dose Escalation and Expansion Phase: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC0-24) of Fruquintinib
hour*nanogram per millimeter (h*ng/mL)Dose Escalation Phase: Fruquintinib 3 mgDose Escalation Phase: Fruquintinib 5 mgDose Expansion Phase, Cohort A: Fruquintinib 5 mgDose Expansion Phase, Cohort B: Fruquintinib 5 mgDose Expansion Phase, Cohort C: Fruquintinib 5 mgDose Expansion Phase, Cohort D: Fruquintinib 5 mgDose Expansion Phase, Cohort E: Fruquintinib 5 mg
Cycle 1 Day 1912 ± 21.52010 ± 19.21340 ± 25.61384 ± 39.01550 ± 46.51821 ± 31.51739 ± 39.8
Cycle 1 Day 143694 ± 17.18249 ± 35.26507 ± 53.75338 ± 28.95833 ± 27.36135 ± 40.16957 ± 25.1
Cycle 1 Day 213731 ± 22.57740 ± 26.74995 ± NA————
SecondaryDose Escalation and Expansion Phase: Apparent Clearance at Steady State (CL/Fss) of Fruquintinib

CL/Fss was calculated as Dose/AUC0-t. As planned, CL/Fss was assessed at Cycle 1 Days 14 and 21 after multiple dose administration in Dose Escalation Phase and Cohort A of Dose Expansion Phase; and at Cycle 1 Day 14 for Cohort B, C, D, E of Expansion Phase.

Time frame:
Dose Escalation and Cohort A of Expansion Phases: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 14, and 21 of Cycle 1; Cohorts B, C, D, E of Expansion Phase: Predose, 1, 2, 4, 8, 24 hours post-dose on Day 14 of Cycle 1 (Cycle 1 length=28 days)
Reported as:
Mean · milliliter per minute (mL/min)
Dose Escalation and Expansion Phase: Apparent Clearance at Steady State (CL/Fss) of Fruquintinib
milliliter per minute (mL/min)Dose Escalation Phase: Fruquintinib 3 mgDose Escalation Phase: Fruquintinib 5 mgDose Expansion Phase, Cohort A: Fruquintinib 5 mgDose Expansion Phase, Cohort B: Fruquintinib 5 mgDose Expansion Phase, Cohort C: Fruquintinib 5 mgDose Expansion Phase, Cohort D: Fruquintinib 5 mgDose Expansion Phase, Cohort E: Fruquintinib 5 mg
Cycle 1 Day 1414.4 ± 2.9011.1 ± 4.0414.1 ± 7.3116.3 ± 5.1614.8 ± 3.9214.7 ± 7.1812.3 ± 2.80
Cycle 1 Day 2114.1 ± 3.0711.3 ± 2.8317.5 ± NA————
SecondaryDose Escalation and Expansion Phase: Accumulation Ratio Based on Cmax of Fruquintinib

Accumulation ratio based on Cmax for Cycle 1 Day 14 was calculated as Day 14 Cmax /Day 1 Cmax and for Cycle 1 Day 21 was calculated as Day 21 Cmax /Day 1 Cmax. Accumulation ratio based on Cmax of fruquintinib was reported.

Time frame:
Dose Escalation and Cohort A of Expansion Phases: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 14 and 21 of Cycle 1; Cohorts B, C, D, E of Expansion Phase: Predose, 1, 2, 4, 8, 24 hours post-dose on Day 14 of Cycle 1 (Cycle 1 length=28 days)
Reported as:
Mean · ratio
Dose Escalation and Expansion Phase: Accumulation Ratio Based on Cmax of Fruquintinib
ratioDose Escalation Phase: Fruquintinib 3 mgDose Escalation Phase: Fruquintinib 5 mgDose Expansion Phase, Cohort A: Fruquintinib 5 mgDose Expansion Phase, Cohort B: Fruquintinib 5 mgDose Expansion Phase, Cohort C: Fruquintinib 5 mgDose Expansion Phase, Cohort D: Fruquintinib 5 mgDose Expansion Phase, Cohort E: Fruquintinib 5 mg
Cycle 1 Day 144.06 ± 1.423.66 ± 1.423.57 ± 0.2323.32 ± 1.213.44 ± 1.363.22 ± 1.383.40 ± 0.963
Cycle 1 Day 214.22 ± 1.453.47 ± 1.223.40 ± NA————
SecondaryDose Escalation and Expansion Phase: Accumulation Ratio Based on AUC0-24 Hours of Fruquintinib

Accumulation ratio for Cycle 1 Day 14 was calculated as AUC0-24 at Day 14 divided by AUC0-24h at Day 1, and for Cycle 1 Day 21 was calculated as AUC0-24 at Day 21 divided by AUC0-24 at Day 1. Accumulation ratio based on AUC0-24 of fruquintinib was reported.

Time frame:
Dose Escalation and Cohort A of Expansion Phases: Predose, 1, 2, 4, 8, 24 hours post-dose on Days 14 and 21 of Cycle 1; Cohorts B, C, D, E of Expansion Phase: Predose, 1, 2, 4, 8, 24 hours post-dose on Day 14 of Cycle 1 (Cycle 1 length=28 days)
Reported as:
Mean · ratio
Dose Escalation and Expansion Phase: Accumulation Ratio Based on AUC0-24 Hours of Fruquintinib
ratioDose Escalation Phase: Fruquintinib 3 mgDose Escalation Phase: Fruquintinib 5 mgDose Expansion Phase, Cohort A: Fruquintinib 5 mgDose Expansion Phase, Cohort B: Fruquintinib 5 mgDose Expansion Phase, Cohort C: Fruquintinib 5 mgDose Expansion Phase, Cohort D: Fruquintinib 5 mgDose Expansion Phase, Cohort E: Fruquintinib 5 mg
Cycle 1 Day 144.24 ± 1.214.19 ± 1.194.04 ± NA3.87 ± 1.224.38 ± 3.083.73 ± 1.514.37 ± 1.70
Cycle 1 Day 214.36 ± 1.533.90 ± 0.9644.43 ± NA————
SecondaryDose Escalation and Expansion Phase: Objective Response Rate (ORR)

ORR was defined as the percentage of participants with objective complete response (CR) or partial response (PR) response per RECIST version 1.1. As per RECIST 1.1; CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

Time frame:
From the first dose of study drug until first documentation of best overall response (i.e., up to 29 months)
Reported as:
Number · percentage of participants
Dose Escalation and Expansion Phase: Objective Response Rate (ORR)
percentage of participantsDose Escalation Phase: Fruquintinib 3 mgDose Escalation Phase: Fruquintinib 5 mgDose Expansion Phase, Cohort A: Fruquintinib 5 mgDose Expansion Phase, Cohort B: Fruquintinib 5 mgDose Expansion Phase, Cohort C: Fruquintinib 5 mgDose Expansion Phase, Cohort D: Fruquintinib 5 mgDose Expansion Phase, Cohort E: Fruquintinib 5 mg
Dose Escalation and Expansion Phase: Objective Response Rate (ORR)16.7 (0.42 to 64.12)14.3 (0.36 to 57.87)0.0 (0.00 to 45.93)2.4 (0.06 to 12.86)5.1 (0.63 to 17.32)0.0 (0.00 to 30.85)0.0 (0.00 to 24.71)
SecondaryDose Escalation and Expansion Phase: Disease Control Rate (DCR)

DCR was defined as the percentage of participants with a best overall response (BOR) of confirmed CR, confirmed PR or stable disease (SD) (for 7 weeks) per RECIST version 1.1. As per RECIST 1.1; CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study \[this might include the baseline sum\]).

Time frame:
From the first dose of study drug until first documentation of best overall response (i.e., up to 29 months)
Reported as:
Number · percentage of participants
Dose Escalation and Expansion Phase: Disease Control Rate (DCR)
percentage of participantsDose Escalation Phase: Fruquintinib 3 mgDose Escalation Phase: Fruquintinib 5 mgDose Expansion Phase, Cohort A: Fruquintinib 5 mgDose Expansion Phase, Cohort B: Fruquintinib 5 mgDose Expansion Phase, Cohort C: Fruquintinib 5 mgDose Expansion Phase, Cohort D: Fruquintinib 5 mgDose Expansion Phase, Cohort E: Fruquintinib 5 mg
Dose Escalation and Expansion Phase: Disease Control Rate (DCR)66.7 (22.28 to 95.67)71.4 (29.04 to 96.33)66.7 (22.28 to 95.67)68.3 (51.91 to 81.92)59.0 (42.10 to 74.43)60.0 (26.24 to 87.84)38.5 (13.86 to 68.42)
SecondaryDose Escalation and Expansion Phase: Duration of Response (DoR)

DoR was defined as the time (in months) from the date of the first objective response (CR or PR) until the date of the documented progression or of death, whichever comes first. DoR was only analyzed for participants whose best overall response (BOR) was either CR or PR. As per RECIST 1.1; CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this might include the baseline sum). DoR was calculated using the Kaplan-Meier method.

Time frame:
From the date of the first objective response (CR or PR) until the date of the documented disease progression or of death, whichever comes first (i.e., up to 29 months)
Reported as:
Median · months
Dose Escalation and Expansion Phase: Duration of Response (DoR)
monthsDose Escalation Phase: Fruquintinib 3 mgDose Escalation Phase: Fruquintinib 5 mgDose Expansion Phase, Cohort A: Fruquintinib 5 mgDose Expansion Phase, Cohort B: Fruquintinib 5 mgDose Expansion Phase, Cohort C: Fruquintinib 5 mgDose Expansion Phase, Cohort D: Fruquintinib 5 mgDose Expansion Phase, Cohort E: Fruquintinib 5 mg
Dose Escalation and Expansion Phase: Duration of Response (DoR)7.56 (NA to NA)NA (NA to NA)—4.04 (NA to NA)NA (5.65 to NA)——
SecondaryDose Escalation and Expansion Phase: Progression Free Survival (PFS)

PFS was defined as the time (in months) from date of first dosing until the date of an objective disease progression as per RECIST version 1.1 or death due to any cause, whichever comes first. PFS was determined using all the assessment data up until the last evaluable visit prior to or on the date of (i) disease progression as defined by RECIST version 1.1 or death; or (ii) withdrawal of consent; or (iii) receiving subsequent anti-cancer therapy, whichever is earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this might include the baseline sum). PFS was calculated using the Kaplan-Meier method.

Time frame:
From date of first dose until the date of an objective disease progression or death due to any cause, whichever comes first (i.e., up to 29 months)
Reported as:
Median · months
Dose Escalation and Expansion Phase: Progression Free Survival (PFS)
monthsDose Escalation Phase: Fruquintinib 3 mgDose Escalation Phase: Fruquintinib 5 mgDose Expansion Phase, Cohort A: Fruquintinib 5 mgDose Expansion Phase, Cohort B: Fruquintinib 5 mgDose Expansion Phase, Cohort C: Fruquintinib 5 mgDose Expansion Phase, Cohort D: Fruquintinib 5 mgDose Expansion Phase, Cohort E: Fruquintinib 5 mg
Dose Escalation and Expansion Phase: Progression Free Survival (PFS)6.90 (0.56 to NA)NA (3.65 to NA)5.49 (1.77 to NA)4.67 (2.76 to 5.32)3.75 (2.00 to 5.49)2.43 (1.74 to 5.06)1.87 (1.15 to 3.94)
SecondaryDose Escalation and Expansion Phase: Overall Survival (OS)

OS was defined as the time interval (in months) between the first dose date and the date of death (any cause). OS was calculated using the Kaplan-Meier method.

Time frame:
From first dose date to the date of death (due to any cause) (i.e., up to 29 months)
Reported as:
Median · months
Dose Escalation and Expansion Phase: Overall Survival (OS)
monthsDose Escalation Phase: Fruquintinib 3 mgDose Escalation Phase: Fruquintinib 5 mgDose Expansion Phase, Cohort A: Fruquintinib 5 mgDose Expansion Phase, Cohort B: Fruquintinib 5 mgDose Expansion Phase, Cohort C: Fruquintinib 5 mgDose Expansion Phase, Cohort D: Fruquintinib 5 mgDose Expansion Phase, Cohort E: Fruquintinib 5 mg
Dose Escalation and Expansion Phase: Overall Survival (OS)22.70 (0.56 to NA)19.58 (6.05 to NA)6.03 (4.24 to NA)8.71 (6.57 to 11.47)10.64 (5.16 to 19.32)12.06 (6.21 to 13.24)8.74 (3.78 to 15.93)
SecondaryDose Escalation and Expansion Phase: Percent Change From Baseline (PCFB) in Tumor Size

Tumor size was estimated using data on sum of diameters of target lesion. Percentage change in tumor size from baseline was determined for participants with measurable disease at baseline and derived by the percentage change in the sum of the diameters of target lesions (TLs) compared to baseline. Baseline was defined as the last evaluable tumor assessment result obtained prior to the first administration of study medication.

Time frame:
Baseline up to 29 months
Reported as:
Mean · percent change
Dose Escalation and Expansion Phase: Percent Change From Baseline (PCFB) in Tumor Size
percent changeDose Escalation Phase: Fruquintinib 3 mgDose Escalation Phase: Fruquintinib 5 mgDose Expansion Phase, Cohort A: Fruquintinib 5 mgDose Expansion Phase, Cohort B: Fruquintinib 5 mgDose Expansion Phase, Cohort C: Fruquintinib 5 mgDose Expansion Phase, Cohort D: Fruquintinib 5 mgDose Expansion Phase, Cohort E: Fruquintinib 5 mg
Dose Escalation and Expansion Phase: Percent Change From Baseline (PCFB) in Tumor Size5.41 ± NA-20.70 ± 16.485-12.92 ± 25.9197.40 ± 23.71319.23 ± 20.808-8.07 ± 8.5749.82 ± 16.824
SecondaryDose Expansion Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

TEAEs were defined as AEs that started or worsened in severity on or after the first dose of study medication and no later than 37 days after the date of last study treatment. A SAE was any AE that had any of the following characteristics: Fatal (that was, the AE actually caused or led to death, except for deaths caused by the progress of disease); Life threatening (that was, AE, in view of the investigator, places participant at immediate risk of death); Required or prolonged inpatient hospitalization (excluding emergency or outpatient treatment); Resulted in persistent or significant disability/incapacity (that was, the AE resulted in substantial disruption of the participant's ability to conduct normal life functions).

Time frame:
From first dose of study drug up to 37 days after last dose of study drug (i.e., up to 29 months)
Reported as:
Count of participants · Participants
Dose Expansion Phase: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsDose Expansion Phase, Cohort A: Fruquintinib 5 mgDose Expansion Phase, Cohort B: Fruquintinib 5 mgDose Expansion Phase, Cohort C: Fruquintinib 5 mgDose Expansion Phase, Cohort D: Fruquintinib 5 mgDose Expansion Phase, Cohort E: Fruquintinib 5 mg
Participants with TEAEs641391414
Participants with serious TEAEs4191424

Adverse events

Collected over From first dose of study drug up to 37 days after last dose of study drug (i.e., up to 29 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Escalation Phase: Fruquintinib 3 mg3/7 (42.9%)3/7 (42.9%)7/7 (100%)
Dose Escalation Phase: Fruquintinib 5 mg2/7 (28.6%)2/7 (28.6%)7/7 (100%)
Dose Expansion Phase, Cohort A: Fruquintinib 5 mg3/6 (50%)4/6 (66.7%)6/6 (100%)
Dose Expansion Phase, Cohort B: Fruquintinib 5 mg30/41 (73.2%)19/41 (46.3%)41/41 (100%)
Dose Expansion Phase, Cohort C: Fruquintinib 5 mg25/40 (62.5%)14/40 (35%)39/40 (97.5%)
Dose Expansion Phase, Cohort D: Fruquintinib 5 mg12/14 (85.7%)2/14 (14.3%)14/14 (100%)
Dose Expansion Phase, Cohort E: Fruquintinib 5 mg12/14 (85.7%)4/14 (28.6%)14/14 (100%)
Most frequent serious events
Showing 10 of 49
Most frequent serious events
EventDose Escalation Phase: Fruquintinib 3 mgDose Escalation Phase: Fruquintinib 5 mgDose Expansion Phase, Cohort A: Fruquintinib 5 mgDose Expansion Phase, Cohort B: Fruquintinib 5 mgDose Expansion Phase, Cohort C: Fruquintinib 5 mgDose Expansion Phase, Cohort D: Fruquintinib 5 mgDose Expansion Phase, Cohort E: Fruquintinib 5 mg
Abdominal painGastrointestinal disorders0/70/71/63/413/400/141/14
Upper gastrointestinal haemorrhageGastrointestinal disorders0/70/71/61/410/400/140/14
Upper respiratory tract infectionInfections and infestations0/70/71/60/410/400/140/14
DyspnoeaRespiratory, thoracic and mediastinal disorders0/70/71/61/411/400/140/14
CoughRespiratory, thoracic and mediastinal disorders0/70/71/60/410/400/140/14
HaemoptysisRespiratory, thoracic and mediastinal disorders0/70/71/60/410/400/140/14
Angina pectorisCardiac disorders0/70/71/60/410/400/140/14
Acquired oesophageal webGastrointestinal disorders1/70/70/60/410/400/140/14
Large intestinal obstructionGastrointestinal disorders1/70/70/61/410/400/140/14
Breast cellulitisInfections and infestations0/71/70/60/410/400/140/14
Most frequent other events
Showing 10 of 221
Most frequent other events
EventDose Escalation Phase: Fruquintinib 3 mgDose Escalation Phase: Fruquintinib 5 mgDose Expansion Phase, Cohort A: Fruquintinib 5 mgDose Expansion Phase, Cohort B: Fruquintinib 5 mgDose Expansion Phase, Cohort C: Fruquintinib 5 mgDose Expansion Phase, Cohort D: Fruquintinib 5 mgDose Expansion Phase, Cohort E: Fruquintinib 5 mg
DiarrhoeaGastrointestinal disorders3/73/75/617/415/405/144/14
HypertensionVascular disorders2/73/75/620/4129/409/146/14
ConstipationGastrointestinal disorders5/73/73/611/416/406/143/14
DysphoniaRespiratory, thoracic and mediastinal disorders2/74/74/613/4110/405/143/14
NauseaGastrointestinal disorders4/74/71/611/416/407/147/14
VomitingGastrointestinal disorders4/74/73/67/413/402/144/14
Weight decreasedInvestigations2/74/70/69/414/401/143/14
Decreased appetiteMetabolism and nutrition disorders2/74/72/614/4110/404/142/14
FatigueGeneral disorders1/73/72/622/4112/408/145/14
HeadacheNervous system disorders1/74/72/611/416/405/147/14

Baseline characteristics

The safety analysis set (SAS) included all participants who received at least 1 dose of the study drug.

Age, Continuous
Age, Continuous(years)Dose Escalation Phase: Fruquintinib 3 mgDose Escalation Phase: Fruquintinib 5 mgDose Expansion Phase, Cohort A: Fruquintinib 5 mgDose Expansion Phase, Cohort B: Fruquintinib 5 mgDose Expansion Phase, Cohort C: Fruquintinib 5 mgDose Expansion Phase, Cohort D: Fruquintinib 5 mgDose Expansion Phase, Cohort E: Fruquintinib 5 mgTotal
Mean61.08 ± 5.56657.72 ± 12.71268.91 ± 8.87958.54 ± 10.18256.94 ± 9.92355.45 ± 13.44350.86 ± 9.15257.45 ± 10.672
Sex: Female, Male
Sex: Female, Male(Participants)Dose Escalation Phase: Fruquintinib 3 mgDose Escalation Phase: Fruquintinib 5 mgDose Expansion Phase, Cohort A: Fruquintinib 5 mgDose Expansion Phase, Cohort B: Fruquintinib 5 mgDose Expansion Phase, Cohort C: Fruquintinib 5 mgDose Expansion Phase, Cohort D: Fruquintinib 5 mgDose Expansion Phase, Cohort E: Fruquintinib 5 mgTotal
Female4632124141486
Male31320160043
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dose Escalation Phase: Fruquintinib 3 mgDose Escalation Phase: Fruquintinib 5 mgDose Expansion Phase, Cohort A: Fruquintinib 5 mgDose Expansion Phase, Cohort B: Fruquintinib 5 mgDose Expansion Phase, Cohort C: Fruquintinib 5 mgDose Expansion Phase, Cohort D: Fruquintinib 5 mgDose Expansion Phase, Cohort E: Fruquintinib 5 mgTotal
Hispanic or Latino11021016
Not Hispanic or Latino66638391313121
Unknown or Not Reported00010102
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose Escalation Phase: Fruquintinib 3 mgDose Escalation Phase: Fruquintinib 5 mgDose Expansion Phase, Cohort A: Fruquintinib 5 mgDose Expansion Phase, Cohort B: Fruquintinib 5 mgDose Expansion Phase, Cohort C: Fruquintinib 5 mgDose Expansion Phase, Cohort D: Fruquintinib 5 mgDose Expansion Phase, Cohort E: Fruquintinib 5 mgTotal
American Indian or Alaska Native00000000
Asian00013015
Native Hawaiian or Other Pacific Islander00000000
Black or African American010440413
White7663333139107
More than one race00000000
Unknown or Not Reported00030104
08

Study locations

9 sites
  • Mayo Clinic Arizona
    Phoenix, Arizona 85054, United States
  • California Cancer Care Associates for Research & Excellence, Inc.
    San Marcos, California 92069, United States
  • St. Joseph Heritage Healthcare
    Santa Rosa, California 95403, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • Hem-Onc Associates of the Treasure Coast
    Port Saint Lucie, Florida 34952, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55902, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Vanderbilt Ingram Cancer Center
    Nashville, Tennessee 37232, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Dec 2022, 60 months.

Results were first posted in Sep 2024, 1 year 9 months after primary completion.

Of 51 industry-sponsored phase 1 interventional studies under Colonic Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 64. This study's 60 months is above that.

Counting every sponsor, half of 116 studies reached it within 48 months; a quarter within 32 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2017
First posted
Aug 16, 2017
StartActual
Dec 11, 2017
Primary completionActual
Dec 13, 2022
CompletionActual
Mar 30, 2023
Results first posted
Sep 25, 2024
Last update
Sep 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03251378
Responsible party
Sponsor
First posted
Aug 16, 2017
Start date
Dec 11, 2017
Primary completion
Dec 13, 2022
Completion
Mar 30, 2023
Results posted
Sep 25, 2024
Last update
Sep 25, 2024

Study contacts

William Schelman
study director · HUTCHMED International

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HMPL-013

Start the discussion